Overview
- Product nameAnti-LMW Kininogen antibody (Biotin)See all LMW Kininogen primary antibodies ...
- DescriptionRabbit polyclonal to LMW Kininogen (Biotin)
- ConjugationBiotin
- Tested applicationsWB, IP, ELISA, RIA more details
- Species reactivityReacts with: Human
- Immunogen
Kininogen (LMW) purified from human plasma
Properties
- FormLiquid
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.01% Thimerosal (merthiolate)
Constituents: 50% Glycerol, PBS, pH 7.5 -
Concentration information loading... - PurityProtein G purified
- Clonality Polyclonal
- IsotypeIgG
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab79651 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| WB | WB: Use a concentration of 20 µg/ml. Predicted molecular weight: 48 kDa. |
| IP | IP: Use at an assay dependent dilution. |
| ELISA | ELISA: Use a concentration of 4 - 10 µg/ml. |
| RIA | RIA: Use a concentration of 4 - 10 µg/ml. |
Target
- Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
- Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
- Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
- Sequence similaritiesContains 3 cystatin kininogen-type domains.
- Post-translational
modificationsBradykinin is released from kininogen by plasma kallikrein.
Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
Phosphorylation sites are present in the extracellular medium.
N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans. - Cellular localizationSecreted > extracellular space.
-
Database links
- Entrez Gene: 3827 Human
- Omim: 612358 Human
- SwissProt: P01042 Human
- Unigene: 77741 Human
Target information above from: UniProt accession
P01042
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- Alpha-2-thiol proteinase inhibitor antibodyBDK antibodyBK antibody
- Fitzgerald factor antibodyHigh molecular weight kininogen antibodyHMWK antibodyIle-Ser-Bradykinin antibodyKallidin I antibodyKallidin II antibodyKininogen 1 antibodyKNG antibodyKNG1 antibodyKNG1_HUMAN antibodyLMW antibodyLow molecular weight growth promoting factor antibodyLow molecular weight growth-promoting factor antibodyLow molecular weight kininogen antibodyWilliams-Fitzgerald-Flaujeac factor antibody
see all
References for Anti-LMW Kininogen antibody (Biotin) (ab79651)
ab79651 has not yet been referenced specifically in any publications.
